Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab
Background Infliximab (IFX) is a monoclonal antibody against tumour necrosis factor α that is effective for treating spondyloarthritis (SpA). However, after initial success of the drug some patients lose responsiveness or develop infusion reactions, which may be related to the development of antibod...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2012-12, Vol.71 (12), p.1955-1960 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1960 |
|---|---|
| container_issue | 12 |
| container_start_page | 1955 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 71 |
| creator | Plasencia, Chamaida Pascual-Salcedo, Dora Nuño, Laura Bonilla, Gema Villalba, Alejandro Peiteado, Diana Díez, Jesús Nagore, Daniel del Agua, Ainhoa Ruiz Moral, Rosario Martin-Mola, Emilio Balsa, Alejandro |
| description | Background Infliximab (IFX) is a monoclonal antibody against tumour necrosis factor α that is effective for treating spondyloarthritis (SpA). However, after initial success of the drug some patients lose responsiveness or develop infusion reactions, which may be related to the development of antibodies against the drug. Objective To investigate the clinical relevance of antibodies to infliximab (ATI) formation in patients with SpA undergoing IFX treatment over a prolonged period. Methods 94 patients with SpA treated with IFX from 1999 to 2010 were studied. Their clinical characteristics, serum trough IFX levels and ATI status were evaluated for a mean of 6.99 (95% CI:6.28 to 7.7) years. Clinical activity and improvement were measured using the Ankylosing Spondylitis Disease Activity Score (ASDAS): inactive 4 years). Results ATI were detected in 24 (25.5%) patients. The patients with ATI had higher ASDAS scores than those without ATI (2.55±0.89 vs 1.79±1.04, p=0.038 at 6 months; 1.95±0.67 vs 1.67±0.71, p=0.042 at 1 year; 2.52±0.99 vs 1.53±0.81, p=0.024 at >4 years). Eleven patients (12%) developed infusion-related reactions, and of these, ATI were present in eight patients (73%). The patients with infusion-related reactions had higher ATI titres (median 12 931 AU/ml, IQR 853–82 437) vs median 2454 AU/ml, IQR 449–7718, p=0.028) and shorter survival (4.25 years vs 8.19 years, p |
| doi_str_mv | 10.1136/annrheumdis-2011-200828 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1139628421</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1139628421</sourcerecordid><originalsourceid>FETCH-LOGICAL-b592t-4c7ed5319f6825f89e2b0603ad9801b62aec25d7723fdf3d9fc0cded86c466b3</originalsourceid><addsrcrecordid>eNqNkcluFDEQhi0EIkPgFaAlhJRLg5f20kc0ghARlkPEIRfL7SXjodue2G6ReXs86mGEOHGpUtlf_aqqH4BXCL5FiLB3KoS0sfNkfG4xRKgGKLB4BFaoY6JWDD4GKwghabue8TPwLOdtLaFA4ik4w5gyArFYAXcV3DjboG0TXeOnaQ7xzgavfdk3MTRlYxvrnNdK7w_EGMNdsWlqSrKqTDaUw2vexWD2Y1SpbJIvPje_fNk0vmr7Bz-p4Tl44tSY7YtjPgc3Hz_crD-1198ur9bvr9uB9ri0nebWUIJ6xwSmTvQWD3UVokwvIBoYVlZjajjHxBlHTO801MYawXTH2EDOwcUiu0vxfra5yMlnbcdRBRvnLOvteoZFh1FFX_-DbuOcQh1OIs654KLvSKX4QukUc07WyV2q-6S9RPCgxuRfTsiDE3Jxona-POrPw2TNqe_P6Svw5giorNXokgq6apw4RgWkrK9cu3A-F_tw-lfpp2SccCq__lhLJujt5-9fqLytPF74Ydr-97S_AWRMtik</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777878943</pqid></control><display><type>article</type><title>Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><creator>Plasencia, Chamaida ; Pascual-Salcedo, Dora ; Nuño, Laura ; Bonilla, Gema ; Villalba, Alejandro ; Peiteado, Diana ; Díez, Jesús ; Nagore, Daniel ; del Agua, Ainhoa Ruiz ; Moral, Rosario ; Martin-Mola, Emilio ; Balsa, Alejandro</creator><creatorcontrib>Plasencia, Chamaida ; Pascual-Salcedo, Dora ; Nuño, Laura ; Bonilla, Gema ; Villalba, Alejandro ; Peiteado, Diana ; Díez, Jesús ; Nagore, Daniel ; del Agua, Ainhoa Ruiz ; Moral, Rosario ; Martin-Mola, Emilio ; Balsa, Alejandro</creatorcontrib><description>Background Infliximab (IFX) is a monoclonal antibody against tumour necrosis factor α that is effective for treating spondyloarthritis (SpA). However, after initial success of the drug some patients lose responsiveness or develop infusion reactions, which may be related to the development of antibodies against the drug. Objective To investigate the clinical relevance of antibodies to infliximab (ATI) formation in patients with SpA undergoing IFX treatment over a prolonged period. Methods 94 patients with SpA treated with IFX from 1999 to 2010 were studied. Their clinical characteristics, serum trough IFX levels and ATI status were evaluated for a mean of 6.99 (95% CI:6.28 to 7.7) years. Clinical activity and improvement were measured using the Ankylosing Spondylitis Disease Activity Score (ASDAS): inactive <1.3, moderate ≥1.3 and <2.1, high ≥2.1–≤3.5, and very high >3.5 at three time points (6 months, 12 months and >4 years). Results ATI were detected in 24 (25.5%) patients. The patients with ATI had higher ASDAS scores than those without ATI (2.55±0.89 vs 1.79±1.04, p=0.038 at 6 months; 1.95±0.67 vs 1.67±0.71, p=0.042 at 1 year; 2.52±0.99 vs 1.53±0.81, p=0.024 at >4 years). Eleven patients (12%) developed infusion-related reactions, and of these, ATI were present in eight patients (73%). The patients with infusion-related reactions had higher ATI titres (median 12 931 AU/ml, IQR 853–82 437) vs median 2454 AU/ml, IQR 449–7718, p=0.028) and shorter survival (4.25 years vs 8.19 years, p<0.001). ATI development occurred more frequently in the patients not receiving methotrexate (20/58 (34.5%) vs 4/36 (11.1%), p=0.011). Conclusion In patients with SpA treated with IFX, ATI formation is associated with a poor clinical response, the appearance of infusion reactions and the discontinuation of treatment.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2011-200828</identifier><identifier>PMID: 22563028</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>Adult ; Antibodies - blood ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal - blood ; Antibodies, Monoclonal - immunology ; Antibody Specificity ; Antirheumatic Agents - administration & dosage ; Antirheumatic Agents - blood ; Antirheumatic Agents - immunology ; Arthritis ; Biological and medical sciences ; Biological products ; Community Mental Health Services ; Disease ; Diseases of the osteoarticular system ; Diseases of the spine ; Drug dosages ; Drug Resistance - immunology ; Female ; Humans ; Immunoglobulins ; Immunomodulators ; Inflammatory bowel disease ; Infliximab ; Infusions, Intravenous ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Retrospective Studies ; Rheumatism ; Severity of Illness Index ; Spondylarthritis - drug therapy ; Spondylarthritis - immunology ; Studies ; Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><ispartof>Annals of the rheumatic diseases, 2012-12, Vol.71 (12), p.1955-1960</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2015 INIST-CNRS</rights><rights>Copyright: 2012 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b592t-4c7ed5319f6825f89e2b0603ad9801b62aec25d7723fdf3d9fc0cded86c466b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/71/12/1955.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/71/12/1955.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,3196,23571,27924,27925,77472,77503</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26580569$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22563028$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Plasencia, Chamaida</creatorcontrib><creatorcontrib>Pascual-Salcedo, Dora</creatorcontrib><creatorcontrib>Nuño, Laura</creatorcontrib><creatorcontrib>Bonilla, Gema</creatorcontrib><creatorcontrib>Villalba, Alejandro</creatorcontrib><creatorcontrib>Peiteado, Diana</creatorcontrib><creatorcontrib>Díez, Jesús</creatorcontrib><creatorcontrib>Nagore, Daniel</creatorcontrib><creatorcontrib>del Agua, Ainhoa Ruiz</creatorcontrib><creatorcontrib>Moral, Rosario</creatorcontrib><creatorcontrib>Martin-Mola, Emilio</creatorcontrib><creatorcontrib>Balsa, Alejandro</creatorcontrib><title>Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Background Infliximab (IFX) is a monoclonal antibody against tumour necrosis factor α that is effective for treating spondyloarthritis (SpA). However, after initial success of the drug some patients lose responsiveness or develop infusion reactions, which may be related to the development of antibodies against the drug. Objective To investigate the clinical relevance of antibodies to infliximab (ATI) formation in patients with SpA undergoing IFX treatment over a prolonged period. Methods 94 patients with SpA treated with IFX from 1999 to 2010 were studied. Their clinical characteristics, serum trough IFX levels and ATI status were evaluated for a mean of 6.99 (95% CI:6.28 to 7.7) years. Clinical activity and improvement were measured using the Ankylosing Spondylitis Disease Activity Score (ASDAS): inactive <1.3, moderate ≥1.3 and <2.1, high ≥2.1–≤3.5, and very high >3.5 at three time points (6 months, 12 months and >4 years). Results ATI were detected in 24 (25.5%) patients. The patients with ATI had higher ASDAS scores than those without ATI (2.55±0.89 vs 1.79±1.04, p=0.038 at 6 months; 1.95±0.67 vs 1.67±0.71, p=0.042 at 1 year; 2.52±0.99 vs 1.53±0.81, p=0.024 at >4 years). Eleven patients (12%) developed infusion-related reactions, and of these, ATI were present in eight patients (73%). The patients with infusion-related reactions had higher ATI titres (median 12 931 AU/ml, IQR 853–82 437) vs median 2454 AU/ml, IQR 449–7718, p=0.028) and shorter survival (4.25 years vs 8.19 years, p<0.001). ATI development occurred more frequently in the patients not receiving methotrexate (20/58 (34.5%) vs 4/36 (11.1%), p=0.011). Conclusion In patients with SpA treated with IFX, ATI formation is associated with a poor clinical response, the appearance of infusion reactions and the discontinuation of treatment.</description><subject>Adult</subject><subject>Antibodies - blood</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal - blood</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibody Specificity</subject><subject>Antirheumatic Agents - administration & dosage</subject><subject>Antirheumatic Agents - blood</subject><subject>Antirheumatic Agents - immunology</subject><subject>Arthritis</subject><subject>Biological and medical sciences</subject><subject>Biological products</subject><subject>Community Mental Health Services</subject><subject>Disease</subject><subject>Diseases of the osteoarticular system</subject><subject>Diseases of the spine</subject><subject>Drug dosages</subject><subject>Drug Resistance - immunology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulins</subject><subject>Immunomodulators</subject><subject>Inflammatory bowel disease</subject><subject>Infliximab</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><subject>Rheumatism</subject><subject>Severity of Illness Index</subject><subject>Spondylarthritis - drug therapy</subject><subject>Spondylarthritis - immunology</subject><subject>Studies</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkcluFDEQhi0EIkPgFaAlhJRLg5f20kc0ghARlkPEIRfL7SXjodue2G6ReXs86mGEOHGpUtlf_aqqH4BXCL5FiLB3KoS0sfNkfG4xRKgGKLB4BFaoY6JWDD4GKwghabue8TPwLOdtLaFA4ik4w5gyArFYAXcV3DjboG0TXeOnaQ7xzgavfdk3MTRlYxvrnNdK7w_EGMNdsWlqSrKqTDaUw2vexWD2Y1SpbJIvPje_fNk0vmr7Bz-p4Tl44tSY7YtjPgc3Hz_crD-1198ur9bvr9uB9ri0nebWUIJ6xwSmTvQWD3UVokwvIBoYVlZjajjHxBlHTO801MYawXTH2EDOwcUiu0vxfra5yMlnbcdRBRvnLOvteoZFh1FFX_-DbuOcQh1OIs654KLvSKX4QukUc07WyV2q-6S9RPCgxuRfTsiDE3Jxona-POrPw2TNqe_P6Svw5giorNXokgq6apw4RgWkrK9cu3A-F_tw-lfpp2SccCq__lhLJujt5-9fqLytPF74Ydr-97S_AWRMtik</recordid><startdate>20121201</startdate><enddate>20121201</enddate><creator>Plasencia, Chamaida</creator><creator>Pascual-Salcedo, Dora</creator><creator>Nuño, Laura</creator><creator>Bonilla, Gema</creator><creator>Villalba, Alejandro</creator><creator>Peiteado, Diana</creator><creator>Díez, Jesús</creator><creator>Nagore, Daniel</creator><creator>del Agua, Ainhoa Ruiz</creator><creator>Moral, Rosario</creator><creator>Martin-Mola, Emilio</creator><creator>Balsa, Alejandro</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20121201</creationdate><title>Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab</title><author>Plasencia, Chamaida ; Pascual-Salcedo, Dora ; Nuño, Laura ; Bonilla, Gema ; Villalba, Alejandro ; Peiteado, Diana ; Díez, Jesús ; Nagore, Daniel ; del Agua, Ainhoa Ruiz ; Moral, Rosario ; Martin-Mola, Emilio ; Balsa, Alejandro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b592t-4c7ed5319f6825f89e2b0603ad9801b62aec25d7723fdf3d9fc0cded86c466b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Antibodies - blood</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal - blood</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibody Specificity</topic><topic>Antirheumatic Agents - administration & dosage</topic><topic>Antirheumatic Agents - blood</topic><topic>Antirheumatic Agents - immunology</topic><topic>Arthritis</topic><topic>Biological and medical sciences</topic><topic>Biological products</topic><topic>Community Mental Health Services</topic><topic>Disease</topic><topic>Diseases of the osteoarticular system</topic><topic>Diseases of the spine</topic><topic>Drug dosages</topic><topic>Drug Resistance - immunology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulins</topic><topic>Immunomodulators</topic><topic>Inflammatory bowel disease</topic><topic>Infliximab</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><topic>Rheumatism</topic><topic>Severity of Illness Index</topic><topic>Spondylarthritis - drug therapy</topic><topic>Spondylarthritis - immunology</topic><topic>Studies</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Plasencia, Chamaida</creatorcontrib><creatorcontrib>Pascual-Salcedo, Dora</creatorcontrib><creatorcontrib>Nuño, Laura</creatorcontrib><creatorcontrib>Bonilla, Gema</creatorcontrib><creatorcontrib>Villalba, Alejandro</creatorcontrib><creatorcontrib>Peiteado, Diana</creatorcontrib><creatorcontrib>Díez, Jesús</creatorcontrib><creatorcontrib>Nagore, Daniel</creatorcontrib><creatorcontrib>del Agua, Ainhoa Ruiz</creatorcontrib><creatorcontrib>Moral, Rosario</creatorcontrib><creatorcontrib>Martin-Mola, Emilio</creatorcontrib><creatorcontrib>Balsa, Alejandro</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Plasencia, Chamaida</au><au>Pascual-Salcedo, Dora</au><au>Nuño, Laura</au><au>Bonilla, Gema</au><au>Villalba, Alejandro</au><au>Peiteado, Diana</au><au>Díez, Jesús</au><au>Nagore, Daniel</au><au>del Agua, Ainhoa Ruiz</au><au>Moral, Rosario</au><au>Martin-Mola, Emilio</au><au>Balsa, Alejandro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2012-12-01</date><risdate>2012</risdate><volume>71</volume><issue>12</issue><spage>1955</spage><epage>1960</epage><pages>1955-1960</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background Infliximab (IFX) is a monoclonal antibody against tumour necrosis factor α that is effective for treating spondyloarthritis (SpA). However, after initial success of the drug some patients lose responsiveness or develop infusion reactions, which may be related to the development of antibodies against the drug. Objective To investigate the clinical relevance of antibodies to infliximab (ATI) formation in patients with SpA undergoing IFX treatment over a prolonged period. Methods 94 patients with SpA treated with IFX from 1999 to 2010 were studied. Their clinical characteristics, serum trough IFX levels and ATI status were evaluated for a mean of 6.99 (95% CI:6.28 to 7.7) years. Clinical activity and improvement were measured using the Ankylosing Spondylitis Disease Activity Score (ASDAS): inactive <1.3, moderate ≥1.3 and <2.1, high ≥2.1–≤3.5, and very high >3.5 at three time points (6 months, 12 months and >4 years). Results ATI were detected in 24 (25.5%) patients. The patients with ATI had higher ASDAS scores than those without ATI (2.55±0.89 vs 1.79±1.04, p=0.038 at 6 months; 1.95±0.67 vs 1.67±0.71, p=0.042 at 1 year; 2.52±0.99 vs 1.53±0.81, p=0.024 at >4 years). Eleven patients (12%) developed infusion-related reactions, and of these, ATI were present in eight patients (73%). The patients with infusion-related reactions had higher ATI titres (median 12 931 AU/ml, IQR 853–82 437) vs median 2454 AU/ml, IQR 449–7718, p=0.028) and shorter survival (4.25 years vs 8.19 years, p<0.001). ATI development occurred more frequently in the patients not receiving methotrexate (20/58 (34.5%) vs 4/36 (11.1%), p=0.011). Conclusion In patients with SpA treated with IFX, ATI formation is associated with a poor clinical response, the appearance of infusion reactions and the discontinuation of treatment.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>22563028</pmid><doi>10.1136/annrheumdis-2011-200828</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2012-12, Vol.71 (12), p.1955-1960 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1139628421 |
| source | MEDLINE; BMJ Journals - NESLi2 |
| subjects | Adult Antibodies - blood Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - blood Antibodies, Monoclonal - immunology Antibody Specificity Antirheumatic Agents - administration & dosage Antirheumatic Agents - blood Antirheumatic Agents - immunology Arthritis Biological and medical sciences Biological products Community Mental Health Services Disease Diseases of the osteoarticular system Diseases of the spine Drug dosages Drug Resistance - immunology Female Humans Immunoglobulins Immunomodulators Inflammatory bowel disease Infliximab Infusions, Intravenous Male Medical sciences Middle Aged Pharmacology. Drug treatments Retrospective Studies Rheumatism Severity of Illness Index Spondylarthritis - drug therapy Spondylarthritis - immunology Studies Tumor Necrosis Factor-alpha - antagonists & inhibitors |
| title | Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A42%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Influence%20of%20immunogenicity%20on%20the%20efficacy%20of%20longterm%20treatment%20of%20spondyloarthritis%20with%20infliximab&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Plasencia,%20Chamaida&rft.date=2012-12-01&rft.volume=71&rft.issue=12&rft.spage=1955&rft.epage=1960&rft.pages=1955-1960&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2011-200828&rft_dat=%3Cproquest_cross%3E1139628421%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777878943&rft_id=info:pmid/22563028&rfr_iscdi=true |